Circassia makes Phase II progress with hay fever vaccine
This article was originally published in Scrip
Executive Summary
Following on from the progress with its cat allergy vaccine, Circassia has now reported positive Phase II results for its ToleroMune hay fever vaccine, and said it has begun a final Phase II study of the treatment.